mutated-CALR peptide vaccine / Icahn School of Medicine at Mount Sinai - LARVOL DELTA

Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms. (PubMed, Leukemia) - "Clinically, CALR-mutated MPNs affect younger patients, exhibit thrombocytosis and progressive anemia, and, in MF patients, are associated with a superior survival compared with JAK2- or MPL-mutated disease, yet responses to hydroxyurea and ruxolitinib remain inferior...Mutant CALR peptide vaccines induce T cell responses but have failed to result in hematologic or molecular responses...Preclinical antibody-drug conjugates, bispecific T-cell engagers, and chimeric antigen receptor T cell (CAR-T) cells also show potent, selective mutant-cell killing. Here we review the basis and ongoing translational and clinical efforts in the development of CALR-targeted immunotherapies that offer a potential shift from symptom management to disease-modifying treatment in this molecularly defined MPN subset."

CALR • IO biomarker • Journal • Review • Essential Thrombocythemia • Hematological Disorders • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Thrombocytosis • CALR • JAK2

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Marina Kremyanskaya | Trial completion date: Mar 2026 ➔ Mar 2027 | Trial primary completion date: Mar 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • Essential Thrombocythemia • Hematological Disorders • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Thrombocytosis • CALR

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Marina Kremyanskaya | Trial completion date: Jan 2025 ➔ Mar 2026 | Trial primary completion date: Jan 2024 ➔ Mar 2026

Trial completion date • Trial primary completion date • Essential Thrombocythemia • Hematological Disorders • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Thrombocytosis • CALR

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Marina Kremyanskaya | Not yet recruiting ➔ Recruiting

Enrollment open • Essential Thrombocythemia • Hematological Disorders • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Thrombocytosis • CALR • TMB

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Michal Bar-Natan | Trial completion date: Sep 2023 ➔ Jan 2025 | Initiation date: Sep 2021 ➔ Jul 2022 | Trial primary completion date: Sep 2022 ➔ Jan 2024

Trial completion date • Trial initiation date • Trial primary completion date • Hematological Disorders • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Thrombocytosis • CALR • TMB